Ｒｅｃｏｍｂｉｎａｎｔ　ｈｕｍａｎ　ｅｒｙｔｈｒｏｐｏｉｅｔｉｎ投与が糖尿病透析患者のＨｂＡ１ｃ値に及ぼす影響

DOI 被引用文献7件

書誌事項

タイトル別名
  • Effect of recombinant human erythropoietin therapy on HbA1c in diabetic Patients undergoing hemodialysis.

この論文をさがす

抄録

HbA1c is a useful parameter in controlling blood glucose levels in diabetic patients undergoing hemodialysis, however, it undergoes apparent decreases after initiation of recombinant human erythropoietin therapy, making changes in it sometimes difficult to interpret as a parameter of diabetic control. In the present study, therefore, we assessed patterns of changes in its levels after initiation of erythropoietin therapy in relation to changes in hemoglobin levels.<br>In the patients included in the present study, diabetic control tended to deteriorate after the start of erythropoietin therapy judged on the basis of mean fructosamine levels, while HbA1c tended to decrease in all patients. Increases in erythropoiesis in response to erythropoietin seemed to contribute to decreases in HbA1c. Comparison of time elapsed until maximum hemoglobin levels and minimum HbA1c levels were observed after initiating erythropoietin therapy showed that minimum HbA1c levels occur earlier than maximum hemoglobin levels. There was no correlation, however, between the improvement in hemoglobin levels (the difference between maximum and baseline hemoglobin levels) and the decrease in HbA1c levels (the difference between minimum and baseline HbA1c levels). Therefore, it was difficult to project patterns of changes in HbA1c levels after initiation of erythropoietin therapy in relation to changes in hemoglobin.

収録刊行物

被引用文献 (7)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ